UBS Group’s Trillium Therapeutics Inc. TRIL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,355
| Closed | -$24K | – | 11340 |
|
|
2021
Q3 | $24K | Sell |
1,355
-1,264,467
| -100% | -$14.8M | ﹤0.01% | 7002 |
|
|
2021
Q2 | $12.3M | Sell |
1,265,822
-56,762
| -4% | -$534K | ﹤0.01% | 1859 |
|
|
2021
Q1 | $14.2M | Buy |
1,322,584
+577,954
| +78% | +$7.15M | ﹤0.01% | 1672 |
|
|
2020
Q4 | $11M | Buy |
744,630
+743,813
| +91,042% | +$10.7M | ﹤0.01% | 1776 |
|
|
2020
Q3 | $12K | Sell |
817
-4,483
| -85% | -$44.7K | ﹤0.01% | 6732 |
|
|
2020
Q2 | $43K | Sell |
5,300
-6,013
| -53% | -$37.2K | ﹤0.01% | 6003 |
|
|
2020
Q1 | $46K | Buy |
+11,313
| New | +$42.8K | ﹤0.01% | 5906 |
|
|
2019
Q4 | – | Sell |
-29,208
| Closed | -$9K | – | 8579 |
|
|
2019
Q3 | $9K | Buy |
29,208
+14,143
| +94% | +$4.78K | ﹤0.01% | 7242 |
|
|
2019
Q2 | $5K | Sell |
15,065
-1,441
| -9% | -$743 | ﹤0.01% | 7412 |
|
|
2019
Q1 | $11K | Buy |
16,506
+11,040
| +202% | +$13.5K | ﹤0.01% | 6781 |
|
|
2018
Q4 | $9K | Buy |
5,466
+2,957
| +118% | +$8.88K | ﹤0.01% | 7310 |
|
|
2018
Q3 | $15K | Buy |
2,509
+1,706
| +212% | +$9.62K | ﹤0.01% | 6976 |
|
|
2018
Q2 | $5K | Buy |
803
+322
| +67% | +$2.05K | ﹤0.01% | 7495 |
|
|
2018
Q1 | $3K | Buy |
+481
| New | +$3.65K | ﹤0.01% | 7467 |
|
|
2017
Q4 | – | Sell |
-1,230
| Closed | -$6K | – | 8218 |
|
|
2017
Q3 | $6K | Buy |
+1,230
| New | +$5.78K | ﹤0.01% | 7173 |
|
|
2017
Q2 | – | Sell |
-1,997
| Closed | -$12K | – | 8127 |
|
|
2017
Q1 | $12K | Buy |
1,997
+720
| +56% | +$4.22K | ﹤0.01% | 6522 |
|
|
2016
Q4 | $7K | Buy |
1,277
+1,077
| +539% | +$10.7K | ﹤0.01% | 7113 |
|
|
2016
Q3 | $3K | Buy |
200
+34
| +20% | +$391 | ﹤0.01% | 7330 |
|
|
2016
Q2 | $1K | Buy |
+166
| New | +$1.73K | ﹤0.01% | 7595 |
|
|
2016
Q1 | – | Sell |
-2,014
| Closed | -$25K | – | 8396 |
|
|
2015
Q4 | $25K | Buy |
2,014
+889
| +79% | +$12.4K | ﹤0.01% | 6529 |
|
|
2015
Q3 | $15K | Buy |
+1,125
| New | +$20.7K | ﹤0.01% | 6978 |
|
Other funds holding TRIL
UBS Group's TRIL Position: Q4 2021 in Review
UBS Group sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 1,355 shares — an estimated $24K sold.
UBS Group first reported a position in TRIL in Q3 2015 and held it in 21 quarters. The position peaked at $14.2M in Q1 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.
- UBS Group reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
- UBS Group sold 1,355 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $24K.
- UBS Group first reported a position in Trillium Therapeutics Inc. in Q3 2015 and held it in 21 quarters.
- UBS Group's Trillium Therapeutics Inc. position peaked at $14.2M in Q1 2021.
- 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.
Based on UBS Group's 13F filing for Q4 2021, filed 14 Feb 2022.